NPHLA Daily — November 6, 2026

Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.

Top development today

What changed today in Metabolic: 4 trial updates, 3 new studies

NPHLA tracked 7 new official records on this desk today: 4 trial updates, 3 new studies. First: Trial status changed to “Recruiting”: MARITIME-T2D-3 (Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes)

Metabolic signal

What changed today in Metabolic: 3 new studies

NPHLA tracked 3 new official records on this desk today: 3 new studies. First: New research in Expert review of clinical pharmacology: “Rethinking endpoints for anti-obesity pharmacotherapy in patients with hr+ early breast cancer receiving endocrine therapy: from body weight…

Aesthetics & Longevity signal

What changed today in Aesthetics & Longevity: 4 trial updates, 1 new study

NPHLA tracked 5 new official records on this desk today: 4 trial updates, 1 new study. First: New trial registered: Exosomes for Striae Distensae

AI & Technology signal

What changed today in AI & Technology: 2 new studies, 1 final rule

NPHLA tracked 3 new official records on this desk today: 2 new studies, 1 final rule. First: New research in Journal of the American Veterinary Medical Association: “Beyond diagnostics: a scoping review of generative artificial intelligence for clinical documentation and client…

One thing worth watching

Comments close: Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information…

November 26, 2026 — verified from the Federal Register comments_close_on.

5 things to know

Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.